| scholarly article | Q13442814 |
| P50 | author | Timothy Hla | Q39514781 |
| P2093 | author name string | Edi Brogi | |
| Andrew J Dannenberg | |||
| Kotha Subbaramaiah | |||
| Clifford Hudis | |||
| Louise R Howe | |||
| Catherine H Liu | |||
| Elisa R Port | |||
| Jack Fishman | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5504-5511 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism | |
| P478 | volume | 66 |
| Q37693261 | 'Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption'. |
| Q36635831 | Aromatase expression predicts survival in women with early-stage non small cell lung cancer |
| Q27003937 | COX-2 and PGE2-dependent immunomodulation in breast cancer |
| Q38474547 | COX2 overexpression is a prognostic marker for Stage III breast cancer |
| Q36745491 | Caloric restriction reverses obesity-induced mammary gland inflammation in mice |
| Q33796582 | Cancer inflammation and regulatory T cells |
| Q59135502 | Celecoxib in breast cancer prevention and therapy |
| Q36643107 | Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model |
| Q37033840 | Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid |
| Q40034911 | EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange |
| Q53176610 | EP4 as a Therapeutic Target for Aggressive Human Breast Cancer. |
| Q45788393 | Endocrine and targeted treatments for breast cancer |
| Q35578981 | Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. |
| Q34570235 | Estrogen as Jekyll and Hyde: regulation of cell death |
| Q26739934 | Evidence to Support the Anti-Cancer Effect of Olive Leaf Extract and Future Directions |
| Q37315920 | Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis |
| Q34538422 | Growth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms |
| Q37270033 | HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer |
| Q36157213 | HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis |
| Q36903378 | HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. |
| Q38755170 | Hsp90 and PKM2 Drive the Expression of Aromatase in Li-Fraumeni Syndrome Breast Adipose Stromal Cells |
| Q37088155 | Impact of cyclooxygenase-2 over-expression on the prognosis of breast cancer patients |
| Q36099670 | Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women |
| Q34338501 | Increasing CD44+/CD24(-) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis |
| Q28218639 | Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer |
| Q35091234 | Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer |
| Q36733703 | Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum |
| Q42669881 | Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer |
| Q35870384 | Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer |
| Q43061636 | Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. |
| Q28261025 | Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells |
| Q39778278 | Modulation of tumorigenesis and oestrogen receptor-alpha expression by cell culture conditions in a stem cell-derived breast epithelial cell line. |
| Q38046127 | Molecular mechanisms of melatonin's inhibitory actions on breast cancers. |
| Q37478905 | Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. |
| Q35227086 | Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. |
| Q34764480 | Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland |
| Q36959883 | Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1. |
| Q58647305 | Preclinical Assays for Identifying Cancer Chemopreventive Phytochemicals |
| Q37302387 | Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms |
| Q37118177 | Reengineering dendritic cell-based anti-cancer vaccines |
| Q33678686 | Regulation of aromatase induction by nuclear receptor coregulator PELP1 |
| Q50592584 | Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. |
| Q37435616 | Targeting aromatase and estrogen signaling in human non-small cell lung cancer |
| Q28271388 | Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer |
| Q38786791 | The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives |
| Q39672633 | The role of cyclooxygenase-2-dependent signaling via cyclic AMP response element activation on aromatase up-regulation by o,p′-DDT in human breast cancer cells |
| Q90394997 | Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile |
| Q33796559 | Unifying roles for regulatory T cells and inflammation in cancer. |
| Q55455337 | [Advances of targeted therapy based on estrogen receptor signaling pathway in lung cancer]. |
Search more.